AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26547351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicyclol combined with ganciclovir (bicyclol 3 mg/kg, twice daily; ganciclovir 5 mg/kg)
Number of subjects: 70
Study 26547351 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir alone (5 mg/kg)
Number of subjects: 70
Study 25618967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chishaodanpi decoction (CSDPD), 100 mL twice a day for 8 weeks, in addition to control treatment.
Number of subjects: 107
Study 25618967 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment with potassium magnesium aspartate, diammonium glycyrrhizinate, glucurolactone, vitamin C, and lamivudine, once a day for 8 weeks.
Number of subjects: 107
Study 25618967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received treatment for 8 weeks.
Number of subjects: 107
Study 22176384 — intervention group
Group type: COMPARATOR
Intervention: Probiotics (exact dosage and duration not specified)
Number of subjects: 126
Study 22176384 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week data collection
Number of subjects: 126
Study 19998861 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation contingent on number of complete (> or = 10 hours) days of data
Number of subjects: 0
Study 19998861 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily journal
Number of subjects: 0
Study 19998861 — intervention group
Group type: EXPERIMENTAL
Intervention: Three phone calls
Number of subjects: 0
Study 19998861 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 17385117 — intervention group
Group type: EXPERIMENTAL
Intervention: SLT with SLT-System I (Glautec AG, ARC, EC)
Number of subjects: 284
Study 17385117 — intervention group
Group type: EXPERIMENTAL
Intervention: SLT with SLT-System II (Lumenis, Palo Alto, CA)
Number of subjects: 284
Study 17385117 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) with Argus (Aesculap Meditec, EC)
Number of subjects: 284
Study 14748891 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L‐T4) treatment for 1 year
Number of subjects: 50
Study 14748891 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 11302598 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-infused silver sulfadiazine cream
Number of subjects: 4
Study 11302598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 9631981 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximally tolerated oral therapy (diuretics, vasodilators, and digitalis)
Number of subjects: 0
Study 9631981 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy at standard doses
Number of subjects: 0
Study 7992670 — intervention group
Group type: EXPERIMENTAL
Intervention: ad lib smoking
Number of subjects: 13
Study 7992670 — intervention group
Group type: COMPARATOR
Intervention: overnight abstinence
Number of subjects: 13
Study 2733125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 36
Study 2733125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 5312248 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (100 mg daily)
Number of subjects: 8169
Study 5312248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8169
Study 5312248 — intervention group
Group type: COMPARATOR
Intervention: Non-medicated internal control
Number of subjects: 8169
Study 31444598 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics machine-learning signature
Number of subjects: 178
Study 31444598 — intervention group
Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 178
Study 31444598 — intervention group
Group type: COMPARATOR
Intervention: LI-RADS scores
Number of subjects: 178
Study 31074844 — intervention group
Group type: EXPERIMENTAL
Intervention: VA hospital-CLC transitions
Number of subjects: 388339
Study 31074844 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-VA hospital to VA-contracted nursing home transitions
Number of subjects: 388339
Study 31074844 — intervention group
Group type: COMPARATOR
Intervention: VA hospitals
Number of subjects: 388339
Study 31074844 — intervention group
Group type: COMPARATOR
Intervention: Non-VA hospital to VA-contracted nursing homes
Number of subjects: 388339
Study 31074844 — intervention group
Group type: COMPARATOR
Intervention: Non-VA hospital to CLC
Number of subjects: 388339
Study 28423969 — intervention group
Group type: EXPERIMENTAL
Intervention: PULSE Program intervention (self-administered lifestyle intervention focused on weight loss, diet, and exercise)
Number of subjects: 101
Study 28423969 — intervention group
Group type: EXPERIMENTAL
Intervention: PULSE Program intervention
Number of subjects: 101
Study 28423969 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 101
Study 26697487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Intervention (PI) - information booklets, 30 min face-to-face medication education and psychological counseling by clinical pharmacists, 2 sessions per week for 2 months
Number of subjects: 149
Study 26697487 — intervention group
Group type: COMPARATOR
Intervention: Control group - conventional treatment only
Number of subjects: 149
Study 24152861 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 630
Study 24152861 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR
Number of subjects: 630
Study 21696849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrilarm(®) capsules (omega-3 and omega-6), twice a day for 6 months
Number of subjects: 181
Study 21696849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrilarm(®) capsules
Number of subjects: 181
Study 21696849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 18448309 — intervention group
Group type: EXPERIMENTAL
Intervention: Groton Maze Learning Test (GMLT)
Number of subjects: 0
Study 18448309 — intervention group
Group type: COMPARATOR
Intervention: CogState computerized cognitive test battery (CGS)
Number of subjects: 0
Study 16254268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (15 microg kg(‐1) h(‐1)) for 7 days
Number of subjects: 40
Study 12968981 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (Daunoxome) administered as a 1‐ to 2.5 h infusion with doses ranging from 30 to 60 mg m(‐2)
Number of subjects: 24
Study 12968981 — intervention group
Group type: COMPARATOR
Intervention: Liposomal daunorubicin (Daunoxome)
Number of subjects: 24
Study 11090729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg epidural neostigmine
Number of subjects: 58
Study 11090729 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg intraarticular neostigmine
Number of subjects: 58
Study 11090729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg intraarticular neostigmine
Number of subjects: 58
Study 11090729 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - normal saline
Number of subjects: 58
Study 8941095 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary fiber intake (median, 34.8 g/d)
Number of subjects: 21930
Study 8941095 — intervention group
Group type: COMPARATOR
Intervention: Low dietary fiber intake (median, 16.1 g/d)
Number of subjects: 21930
Study 8941095 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble fiber
Number of subjects: 21930
Study 8941095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fiber
Number of subjects: 21930
Study 1417428 — intervention group
Group type: EXPERIMENTAL
Intervention: Active imipramine hydrochloride treatment maintained at an average dose of 200 mg
Number of subjects: 128
Study 1417428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 6433715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation therapy
Number of subjects: 30
Study 6433715 — intervention group
Group type: COMPARATOR
Intervention: Staff attention
Number of subjects: 30
Study 6433715 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital treatment
Number of subjects: 30
Study 30702365 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Navigator (PN) intervention providing individualized support with advance care planning, care coordination, and counseling about diet and mental health.
Number of subjects: 40
Study 30702365 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Navigator (PN) intervention
Number of subjects: 40
Study 29725702 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol Vuse Solo electronic cigarettes (14, 29, and 36 mg nicotine)
Number of subjects: 0
Study 29725702 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol Vuse Solo electronic cigarettes
Number of subjects: 0
Study 29725702 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 0
Study 29725702 — intervention group
Group type: COMPARATOR
Intervention: Menthol cigarettes
Number of subjects: 0
Study 26266775 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected electrical pain stimuli
Number of subjects: 20
Study 26266775 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected electrical pain stimuli
Number of subjects: 20
Study 26266775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpainful stimuli
Number of subjects: 20
Study 26266775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham stimuli
Number of subjects: 20
Study 26266775 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting alert state
Number of subjects: 20
Study 24972761 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention (one-question SMS message at 9:30 am or 6:30 pm for 7 days)
Number of subjects: 59
Study 22399124 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg i.v. Magnesium
Number of subjects: 60
Study 22399124 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 60
Study 20564086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 0
Study 20564086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 0
Study 17628351 — intervention group
Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 211
Study 17628351 — intervention group
Group type: EXPERIMENTAL
Intervention: counseling+transfer
Number of subjects: 211
Study 17628351 — intervention group
Group type: EXPERIMENTAL
Intervention: counseling+methadone
Number of subjects: 211
Study 15894961 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 88
Study 15894961 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive management
Number of subjects: 88
Study 12355576 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) as a topically applied photosensitizer for photodynamic therapy (PDT) with a fixed dose of ALA (200 mg/ml) and escalating radiant energies (50-150 J/cm(2)).
Number of subjects: 40
Study 10930200 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 101
Study 10930200 — intervention group
Group type: COMPARATOR
Intervention: ETT
Number of subjects: 101
Study 8820833 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (first-shock energy programmed at 2 X DFT+, second to fifth shocks at maximum output 34 J)
Number of subjects: 162
Study 8820833 — intervention group
Group type: COMPARATOR
Intervention: Control group (all shocks programmed at 34 J)
Number of subjects: 162
Study 8820833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled data from both groups
Number of subjects: 162
Study 1568519 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (500 lipoproteinlipase releasing units twice daily for 1 month)
Number of subjects: 40
Study 1568519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3917968 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral amino acid-glucose solution for 1 month
Number of subjects: 15
Study 3917968 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution without amino acids
Number of subjects: 15
Study 3917968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Amino acid and Control)
Number of subjects: 15
Study 3917968 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral amino acid-glucose solution
Number of subjects: 15
Study 30871480 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self‐rehabilitation Contract
Number of subjects: 124
Study 30871480 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 124
Study 28338406 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Feedback (PAF)
Number of subjects: 45
Study 28338406 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 45
Study 27102820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine (CYD-TDV)
Number of subjects: 0
Study 27102820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24895381 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week balance training programme (3 times per week)
Number of subjects: 59
Study 24895381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 22456062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound only monitoring group
Number of subjects: 0
Study 22456062 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound plus serum estradiol and progesterone monitoring group
Number of subjects: 0
Study 20662726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (personalized Mediterranean diet, physical activity increase, smoking withdrawal counseling)
Number of subjects: 156
Study 20662726 — intervention group
Group type: COMPARATOR
Intervention: Control group (159 patients)
Number of subjects: 156
Study 20662726 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 156
Study 18760151 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-week intensive progressive strength-power training (n=24)
Number of subjects: 46
Study 18760151 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n=22)
Number of subjects: 46
Study 15903362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 minutes of continuous cycling at 70% of Vo(2)max)
Number of subjects: 10
Study 15903362 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic exercise (intermittent dumbbell squatting at 70% of 1 repetition maximum)
Number of subjects: 10
Study 15903362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aerobic and anaerobic exercise
Number of subjects: 10
Study 15903362 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-exercise measurements)
Number of subjects: 10
Study 12620945 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) with propofol 2.5 mg x kg(‐1) and fentanyl 1 micro g x kg(‐1) maintained with N(2)O‐O(2) 50:50 and desflurane for 30 min
Number of subjects: 12
Study 12620945 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka and orange juice to reach BAC 0.08%)
Number of subjects: 12
Study 12620945 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 12
Study 10488296 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.540 microgram/kg per minute with fentanyl and 50% nitrous oxide)
Number of subjects: 101
Study 10488296 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (1.4% end-tidal concentration with fentanyl and 50% nitrous oxide)
Number of subjects: 101
Study 8763803 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Centred and Self-Directive (PCSD) intervention
Number of subjects: 115
Study 8763803 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care (CC)
Number of subjects: 115
Study 29425120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat plant-based diet (n = 38)
Number of subjects: 75
Study 29425120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diet changes, n = 37)
Number of subjects: 75
Study 27222733 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely monitored adherence
Number of subjects: 184
Study 27222733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose counter adherence
Number of subjects: 184
Study 27222733 — intervention group
Group type: COMPARATOR
Intervention: Good adherence
Number of subjects: 184
Study 24609847 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate education intervention
Number of subjects: 415
Study 24609847 — intervention group
Group type: COMPARATOR
Intervention: General health education (control)
Number of subjects: 415
Study 22403047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Number of subjects: 577
Study 22403047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Number of subjects: 577
Study 22403047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 19811806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group with a Double‐J stent fixed pre‐ESWL
Number of subjects: 60
Study 19811806 — intervention group
Group type: COMPARATOR
Intervention: Non-stented group treated by in situ ESWL
Number of subjects: 60
Study 17696126 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg (n = 627)
Number of subjects: 2113
Study 17696126 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a plus natalizumab 300 mg (n = 589)
Number of subjects: 2113
Study 17696126 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 315)
Number of subjects: 2113
Study 17696126 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta‐1a plus placebo (n = 582)
Number of subjects: 2113
Study 15877671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoetin
Number of subjects: 53
Study 15877671 — intervention group
Group type: COMPARATOR
Intervention: Intravenous darbepoetin
Number of subjects: 53
Study 15877671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes
Number of subjects: 53
Study 12468578 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 21
Study 12468578 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 12468578 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Normotensive Volunteers)
Number of subjects: 21
Study 9796239 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia with 8 mg of 0.5% hyperbaric bupivacaine
Number of subjects: 30
Study 9796239 — intervention group
Group type: COMPARATOR
Intervention: Control group with bilateral spinal anaesthesia using 15 mg of 0.5% hyperbaric bupivacaine
Number of subjects: 30
Study 7638814 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (20 mg)
Number of subjects: 12
Study 7638814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2533763 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg three doses by mouth)
Number of subjects: 21
Study 2533763 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg three doses by mouth)
Number of subjects: 21
Study 2533763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 322787 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal wound drainage
Number of subjects: 246
Study 322787 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic systemic cephaloridine
Number of subjects: 246
Study 322787 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal wound drainage + Prophylactic systemic cephaloridine
Number of subjects: 246
Study 31109415 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle MAP group (65 mmHg ≤ MAP < 70 mmHg)
Number of subjects: 60
Study 31109415 — intervention group
Group type: COMPARATOR
Intervention: Low MAP group (60 mmHg ≤ MAP < 65 mmHg)
Number of subjects: 60
Study 31109415 — intervention group
Group type: COMPARATOR
Intervention: High MAP group (70 mmHg ≤ MAP < 75 mmHg)
Number of subjects: 60
Study 28153215 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative mind-body-spirit intervention (I-BMS)
Number of subjects: 126
Study 26258314 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MHP vaccine
Number of subjects: 127
Study 26258314 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls)
Number of subjects: 127
Study 23793226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca intake
Number of subjects: 24
Study 21751661 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training programme (n = 140; 8 weeks, 60-79% HR max reserve, 45-60 minutes, work/rest ratio of 1:1)
Number of subjects: 245
Study 21751661 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 105; sedentary)
Number of subjects: 245
Study 19383438 — intervention group
Group type: EXPERIMENTAL
Intervention: True needling
Number of subjects: 18
Study 19383438 — intervention group
Group type: COMPARATOR
Intervention: Sham needling
Number of subjects: 18
Study 19383438 — intervention group
Group type: COMPARATOR
Intervention: Overt control (placebo)
Number of subjects: 18
Study 16531619 — intervention group
Group type: COMPARATOR
Intervention: Vascular brachytherapy (n = 125)
Number of subjects: 384
Study 16531619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (n = 259)
Number of subjects: 384
Study 12777368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tick-related educational materials
Number of subjects: 317
Study 12777368 — intervention group
Group type: COMPARATOR
Intervention: General health-related educational materials
Number of subjects: 317
Study 10701035 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine 1.6 ml and 4 mg morphine
Number of subjects: 20
Study 10701035 — intervention group
Group type: COMPARATOR
Intervention: 1% lignocaine 2 ml
Number of subjects: 20
Study 9382669 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for low bone density
Number of subjects: 0
Study 9382669 — intervention group
Group type: COMPARATOR
Intervention: No screening (Control)
Number of subjects: 0
Study 8260181 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum tetranectin levels
Number of subjects: 67
Study 3517321 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 32
Study 3517321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32